NIH R01 · 2025
Dissecting Hepatitis B Vaccine Adjuvant Effects on Immune Responses and the HIV Reservoir in PLWH
Project Summary Hepatitis B virus (HBV) is a leading cause of cirrhosis and liver cancer globally, resulting in over 800,000 deaths annually. Approximately 10% of people living with HIV (PLWH) worldwide are infected with HBV and prevention of HBV infection remains a critical goal in PLWH. Vaccination with ENGERIX-B and other alum adjuvanted hepatitis B surface antigen (HBsAg) vaccines has been the cornerstone of HBV prevention, but the response to current standard vaccination is suboptimal in PLWH. HEPLISAV-B vaccine is HBsAg combined with CpG 1018 adjuvant, a Toll-like receptor 9 (TLR9) agonist. A Phase III trial, A5379, randomized PLWH with a prior history of HBV vaccination who do not…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.